Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | CCNC | P24863 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL27556274 | 0.98 | KMT2A (0.49) | KMT2AFAAHCCNCCDK8ALOX15 | |
| SCHEMBL28088111 | 0.84 | KMT2A (0.47) | KMT2AFAAHCCNCCDK8ALOX15 | |
| SCHEMBL27889782 | 0.81 | KMT2A (0.54) | KMT2AFAAHCCNCCDK8ALOX15 | |
| SCHEMBL29214584 | 0.80 | HCAR2 (0.38) | ALDH1A1KDM4EGAAMAPTTHRB | |
| SCHEMBL3548849 | 0.80 | RAB9A (0.46) | KDM4EMAPTRAB9A | |
| SCHEMBL1893211 | 0.79 | ALDH1A1 (0.51) | KMT2AALDH1A1KDM4EMEN1GAA | |
| SCHEMBL27496070 | 0.79 | TUBB4A (0.45) | FAAHALDH1A1KDM4EMAPK1MAPT | |
| SCHEMBL16005701 | 0.78 | KMT2A (0.54) | KMT2ACCNCCDK8ALOX15ALDH1A1 | |
| SCHEMBL29473372 | 0.78 | KMT2A (0.54) | KMT2ACCNCCDK8ALOX15ALDH1A1 | |
| SCHEMBL27588504 | 0.78 | KMT2A (0.50) | KMT2AFAAHCCNCCDK8ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102307622-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2012-01-04 | — | — | CN | claimed |
| EP-1608662-A1 | GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2005-12-28 | — | — | EP | claimed |
| WO-2004083218-A1 | GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-09-30 | — | — | WO | claimed |
| CN-109966294-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维爱尔兰无限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-109897038-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维爱尔兰无限公司 | 2019-06-18 | — | — | CN | disclosed |
| CN-105829308-B | Isochromene derivatives as phosphoinositide 3-kinase inhibitors | 奇斯药制品公司 | 2019-03-08 | — | — | CN | disclosed |
| CN-106008466-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2018-12-14 | — | — | CN | disclosed |
| CN-106008322-B | sulfonamide derivatives as BC L-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE 公司 | 2018-09-04 | — | — | CN | disclosed |
| CN-108175749-A | The solid dispersions of melt extrusion containing cell death inducer | 艾伯维爱尔兰无限公司 | 2018-06-19 | — | — | CN | disclosed |
| CN-105315259-B | Pyridine amine pyrimidine derivates, its preparation method and application | 上海艾力斯医药科技有限公司 | 2018-03-09 | — | — | CN | disclosed |
| CN-103282025-B | Melt-extruded solid dispersions containing apoptosis-inducing agents | 艾伯维爱尔兰无限公司 | 2018-01-02 | — | — | CN | disclosed |
| US-20080132515-A1 | antiviral agents, in particular against cytomegaloviruses; {2-[4-(4-Fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrido[3,4-d]-pyrimidin-4-yl}acetic acid hydrochloride | BAYER HEALTHCARE AG (DE) | 2008-06-05 | — | — | US | disclosed |
| CN-101081850-A | 7-phenylpyrazolopyridine compounds | EISAI CO LTD (JP) | 2007-12-05 | — | — | CN | disclosed |
| CN-101081853-A | 4- (hydroxymethyl) -2, 6-dimethoxyphenylboronic acid compound | EISAI CO LTD (JP) | 2007-12-05 | — | — | CN | disclosed |
| CN-100338063-C | 7-phenylpyrazolopyridine compounds | EISAI CO LTD (JP) | 2007-09-19 | — | — | CN | disclosed |
| CN-101001842-A | Amido compounds and their use as pharmaceuticals | INCYTE CORP (US) | 2007-07-18 | — | — | CN | disclosed |
| CN-1980925-A | Substituted azaquinazolines with antiviral activity | AICURIS GMBH & CO KG (DE) | 2007-06-13 | — | — | CN | disclosed |
| CN-1705665-A | 7-phenylpyrazolopyridine compounds | EISAI CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| CN-1656079-A | Pyrazole compounds and pharmaceutical compositions containing the same | EISAI CO LTD (JP) | 2005-08-17 | — | — | CN | disclosed |
| CN-1244798-A | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | RHONE POULENC RORER PHARMA (US) | 2000-02-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132515-A1 | antiviral agents, in particular against cytomegaloviruses; {2-[4-(4-Fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrido[3,4-d]-pyrimidin-4-yl}acetic acid hydrochloride | ZC3HAV1, EIF2AK2, IRF3 | KMT2A 1539/4885FAAH 2475/4885CCNC 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.